Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BFRI logo BFRI
Upturn stock ratingUpturn stock rating
BFRI logo

Biofrontera Inc (BFRI)

Upturn stock ratingUpturn stock rating
$0.84
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

09/15/2025: BFRI (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $6.5

1 Year Target Price $6.5

Analysts Price Target For last 52 week
$6.5 Target price
52w Low $0.54
Current$0.84
52w High $1.43

Analysis of Past Performance

Type Stock
Historic Profit -76.01%
Avg. Invested days 34
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 09/15/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 8.97M USD
Price to earnings Ratio -
1Y Target Price 6.5
Price to earnings Ratio -
1Y Target Price 6.5
Volume (30-day avg) 2
Beta 0.5
52 Weeks Range 0.54 - 1.43
Updated Date 09/15/2025
52 Weeks Range 0.54 - 1.43
Updated Date 09/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.82

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -42.34%
Operating Margin (TTM) -56.25%

Management Effectiveness

Return on Assets (TTM) -48.85%
Return on Equity (TTM) -531.54%

Valuation

Trailing PE -
Forward PE 10.52
Enterprise Value 6730293
Price to Sales(TTM) 0.23
Enterprise Value 6730293
Price to Sales(TTM) 0.23
Enterprise Value to Revenue 0.17
Enterprise Value to EBITDA -0.79
Shares Outstanding 10668400
Shares Floating 8482051
Shares Outstanding 10668400
Shares Floating 8482051
Percent Insiders 12.74
Percent Institutions 21.92

ai summary icon Upturn AI SWOT

Biofrontera Inc

stock logo

Company Overview

overview logo History and Background

Biofrontera Inc., was established to commercialize dermatological products. Originally Biofrontera AG, the company focuses on the development and sale of pharmaceutical drugs and medical cosmetics for the treatment and prevention of skin diseases. The company has primarily focused on the treatment of actinic keratoses.

business area logo Core Business Areas

  • Prescription Drugs: Development and commercialization of prescription drugs for the treatment of dermatological conditions, primarily actinic keratosis.
  • Medical Cosmetics: Development and commercialization of medical cosmetic products.

leadership logo Leadership and Structure

The leadership team consists of experienced executives in the pharmaceutical and dermatology sectors. The organizational structure is typical for a publicly traded pharmaceutical company, with departments for R&D, sales, marketing, and operations.

Top Products and Market Share

overview logo Key Offerings

  • Ameluz: A topical prescription drug used in combination with photodynamic therapy (PDT) for the treatment of actinic keratoses of mild to moderate severity on the face and scalp. Market share data varies, but Biofrontera aims to compete with existing treatments like Efudex and Picato. Competing products include: Blue light devices (standalone), Solaraze, Zyclara.

Market Dynamics

industry overview logo Industry Overview

The dermatology market is experiencing growth driven by an aging population and increased awareness of skin conditions. There is increasing demand for non-invasive and effective treatments.

Positioning

Biofrontera Inc. aims to be a leading provider of PDT-based treatments for actinic keratosis. Their competitive advantage lies in their Ameluz product and its efficacy when used with PDT.

Total Addressable Market (TAM)

The TAM for actinic keratosis treatment is significant. Ameluz positioned to capture a reasonable share of this market. Accurate TAM figures in the billions.

Upturn SWOT Analysis

Strengths

  • Proprietary Ameluz formulation
  • Established PDT treatment process
  • Focus on a specific dermatological niche

Weaknesses

  • Reliance on a single key product (Ameluz)
  • Relatively small market capitalization
  • Dependence on reimbursement policies

Opportunities

  • Expansion into new geographic markets
  • Development of new dermatological products
  • Partnerships with dermatology clinics and practices

Threats

  • Competition from established pharmaceutical companies
  • Changes in reimbursement policies
  • Potential for generic competition

Competitors and Market Share

competitor logo Key Competitors

  • LEO Pharma (no public US ticker)
  • Galderma (no public US ticker)
  • Sun Pharmaceutical (SUNPHARMA.NS)

Competitive Landscape

Biofrontera Inc. competes with larger pharmaceutical companies with established dermatology portfolios. Their advantage lies in their specific focus on PDT-based treatments. Their disadvantage is their relatively smaller size and resources.

Growth Trajectory and Initiatives

Historical Growth: Biofrontera has experienced moderate growth in revenue driven by sales of Ameluz. However, profitability has been a challenge.

Future Projections: Future growth will depend on the success of Ameluz in existing markets, expansion into new markets, and the development of new products. Analyst estimates are available on financial websites.

Recent Initiatives: Recent strategic initiatives include efforts to increase sales of Ameluz, expand into new markets, and potentially develop new products or formulations.

Summary

Biofrontera Inc. is a small but focused company in the dermatology market, primarily reliant on its Ameluz product. While it shows promise with PDT treatments, it faces stiff competition and financial challenges typical of growth-stage pharmaceutical firms. Expanding its product line and securing better reimbursement policies will be crucial for its long-term success. Investors should be aware of the risks associated with a small-cap pharmaceutical company.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Biofrontera Inc. Investor Relations
  • Third-party financial analysis websites
  • Industry reports

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on your own due diligence and risk tolerance.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Biofrontera Inc

Exchange NASDAQ
Headquaters Woburn, MA, United States
IPO Launch date 2021-10-29
CEO, President & Chairman Dr. Hermann Luebbert Ph.D.
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 92
Full time employees 92

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.